Get notified when HIND files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Company discloses substantial doubt about ability to continue as going concern due to insufficient cash for 12+ months of operations.
- Material Weakness (new) — Management identified material weaknesses in internal controls due to insufficient accounting and finance resources.
- Auditor Change (new) — Company changed auditors from Haskell & White to Kreit & Chiu in August 2025, shortly after the merger closed.
- Canadian Lap-Band Litigation (removed) — Baseline disclosed pending application to add company as defendant in Canadian Lap-Band litigation; current filing removes all legal proceedings disclosure with no status update.
Vyome completes merger, pivots to clinical-stage biotech; legacy device business sold for $2.25M
Filed March 18, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 4, 2025 · ~2 min read
Key Changes
-
high
Company completed merger with Vyome Therapeutics in August 2025, transforming from weight-loss device maker (ReShape) into clinical-stage pharmaceutical company focused on immune-inflammatory diseases. Simultaneously sold legacy Lap-Band assets to Biorad for $2.25M cash.
MD&A: Merger completion verify on EDGAR → -
high
Strategic pivot announced alongside workforce reduction (43% operating expense cut in 2024), material weakness in financial controls, auditor change (August 2025), and removal of Canadian Lap-Band litigation disclosure, suggesting aspirational rather than executed positioning.
Business, MD&A, Risk Factors view on EDGAR → -
high
Net loss widened to $319,714 in FY2025 from $1.4M prior year, driven by $7.7M in merger-related advisory fees (including $5.9M stock-based compensation). Cash position $5.0M at year-end, supplemented by $5.3M ATM raise through March 2026—sufficient for 15 months but not enough to complete lead program VT-1953 pivotal trial.
MD&A: Financial results verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade HIND commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify